China SFDA Bans Use, Orders Recall Of GSK's Augmentin Antibiotic
This article was originally published in PharmAsia News
Executive Summary
China's State FDA ordered GlaxoSmithKline PLC to recall its Augmentin (amoxicillin) antibiotic from the national market because it contains a banned plasticizer